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This study examined the effect of vilazodone, a combined serotonin (5-HT) reuptake inhibitor and 5-HT1A
receptor partial agonist, paroxetine and ﬂuoxetine on the sensitivity of 5-HT1A autoreceptors of
serotonergic dorsal raphe nucleus neurons in rats. These effects were assessed by determining the
intravenous dose of (7)-8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) required to suppress the
basal ﬁring rate of these neurons by 50% (ID50) in anesthetized rats using in vivo electrophysiology. 5-HT
uptake inhibition was determined by the ability of the compounds to reverse (7)-p-chloroamphetamine
(PCA)-induced rat hypothalamic 5-HT depletion ex vivo. Acute vilazodone administration (0.63 and
2.1 mmol/kg, s.c.), compared with vehicle, signiﬁcantly increased (2–3-fold) the ID50 of 8-OH-DPAT at 4 h,
but not 24 h after administration. Subchronic administration (3 days) signiﬁcantly increased the ID50
value at 4 h (3–4-fold) and at 24 h (2-fold). In contrast, paroxetine and ﬂuoxetine at doses that were
supramaximal for 5-HT uptake inhibition did not signiﬁcantly alter the ID50 value of 8-OH-DPAT
after acute or subchronic administration. Vilazodone antagonized the action of PCA 3.5 h and 5 h after a
single dose (ID50 1.49 and 0.46 mmol/kg, s.c., respectively), but was inactive 18 h post-administration,
corroborating the electrophysiological results at 24 h following acute administration. The results are
consistent with the concept of rapid and, following repeated treatment, prolonged inhibition of 5-HT1A
autoreceptors by vilazodone. This effect could occur by either direct interaction with, or desensitization of,
these receptors, an effect which cannot be ascribed to vilazodone's 5-HT reuptake inhibiting properties.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
Vilazodone is a selective serotonin (5-HT) reuptake inhibitor (SSRI)
and 5-HT1A receptor partial agonist with a novel chemical structure
unrelated to conventional SSRIs (Bartoszyk et al., 1996; Heinrich et al.,
2004). It exhibits anxiolytic-like actions in the ultrasonic vocalizationr B.V.
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Open access under CC BY license.test (Bartoszyk et al., 1997) and antidepressant-like effects in the
forced swim test (Page et al., 2002), and has recently been approved
for the treatment of major depressive disorder (Khan, 2009; Khan
et al., 2011; Laughren et al., 2011; Reed et al., 2012; Rickels et al., 2009).
A signiﬁcant body of evidence suggests that augmenting seroto-
nergic transmission in the CNS, either by inhibition of 5-HT reuptake
and/or by activating 5-HT1A receptors, may be effective approaches for
the pharmacotherapy of depression and anxiety disorders (Heisler
et al., 1998; Klemenhagen et al., 2006; Nutt, 2002). Although only one
5-HT1A agonist (buspirone) is approved for the treatment of anxiety,
several compounds with 5-HT1A agonist/partial agonist activity have
been shown to augment response to other antidepressants (Blier and
Ward, 2003; Charney, 1998; Gammans et al., 1992; Parsey et al., 2006;
Robinson et al., 1990; Rush et al., 2006).
Conversely, one widely-held theory states (for review, see Blier
and Ward (2003)) that increase of 5-HT at terminal synapses
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counteracted by neuronal negative feedback mechanisms mediated
by 5-HT1A autoreceptors. Consequently, increased serotonergic trans-
mission requires chronic SSRI treatment, which gradually desensi-
tizes autoreceptors. The delay in the onset of the therapeutic effects
of SSRIs, which occurs only after chronic treatment (e.g., 2–3 weeks),
supports this view. The attenuation of 5-HT1A receptor-mediated
feedback inhibition via compounds that decrease 5-HT1A receptor
function is an approach that could potentially reduce the time to
onset of antidepressant action by the SSRIs. Therefore, developing
a molecule that inhibits the 5-HT transporter and attenuates the
function of the 5-HT1A receptor offers a potential approach for
decreasing the time of onset of antidepressant action. Vilazodone
combines selective serotonin reuptake inhibition and 5-HT1A recep-
tor partial agonism and may provide beneﬁts in treating major
depressive disorder.
In this study, in vivo extracellular electrophysiological record-
ings of spontaneously active 5-HT neurons in the dorsal raphe
nucleus (DRN) in rats were used to evaluate the hypothesis that
vilazodone produces a more rapid decrease in 5-HT1A autoreceptor
sensitivity compared with conventional SSRIs (Page et al., 2002).
The 5-HT1A receptor agonist (7)-8-hydroxy-2-(di-n-propylamino)-
tetralin (8-OH-DPAT) was used as a pharmacologic probe to assess
changes in 5-HT1A autoreceptor sensitivity following administration of
ﬂuoxetine, paroxetine, or vilazodone either acutely or subchronically.
To establish whether 5-HT uptake inhibition inﬂuences the
results in the electrophysiological studies, we determined the
potency and duration of the action of vilazodone and conventional
SSRIs in the (7)-p-chloro-amphetamine (PCA) model, a functional
neurochemical ex vivo assay. PCA utilizes the 5-HT transporter to
enter 5-HT neurons, causing a signiﬁcant depletion of endogenous
5-HT (Berger et al., 1992). The systemic administration of SSRIs
prior to PCA completely reverses 5-HT depletion and is therefore
widely used to assess in vivo 5-HT reuptake inhibition (Fuller,
1980; Seyfried et al., 1989).2. Material and methods
2.1. Materials
Vilazodone HCl was synthesized in the Medicinal Chemistry
Department, Merck KGaA, Darmstadt. Fluoxetine HCl was a gift
from Eli Lilly. Citalopram HBr was a gift from Lundbeck, and
sertraline HCl and paroxetine HCl, 0.5H2O were gifts from
Pﬁzer and SmithKlineBeecham, respectively. 8-OH-DPAT HBr and
R-(–)-fenﬂuramine were purchased from Research Biochemical
(Natick, MA). PCA and chloral hydrate were obtained from
Sigma-Aldrich (St Louis, MO). All other chemicals were at least of
analytical grade, except the constituents of the mobile phase,
which were of HPLC grade and were obtained from Merck KGaA.
2.2. Animals
For the electrophysiological experiments, male Sprague Dawley
rats (Taconic Farms, Germantown, NY, 150–175 g upon arrival)
were used, housed in the animal care facility at St. John's
University, New York, which is an American Association for
Laboratory Animal Care approved facility. For the neurochemical
studies, male Wistar rats (IVA WiWu; 135–160 g, obtained from
Ivanovas, Kisslegg, Germany) were used housed in the Department
of CNS Research, Merck KGaA, Darmstadt, in accordance with the
German guidelines for care and use of laboratory animals. Vivar-
ium conditions were standardized as follows: temperature,
20–23 1C; relative humidity, 50–60%; 2–4 animals per cage; 12 h
light/12 h dark cycle with lights turned on at 0600–0700 h; foodand water were available ad libitum. Rats were allowed at least
3–4 days acclimation in the vivarium prior to beginning of testing
that occurred during the light cycle. Experimental protocols were
approved by the Regierungspräsidium Darmstadt, Germany or
by the St. John's University Institutional Animal Care and Use
Committee (USA).
2.3. Electrophysiology: in vivo neuronal activity of 5-HT neurons
in the DRN
Rats were anesthetized with chloral hydrate (400 mg/kg, i.p.),
placed on a heating pad (37 1C), and secured in a rat stereotaxic
instrument. A lateral tail vein was catheterized by using a 26 gauge
3/8 in. needle. Additional doses of chloral hydrate were adminis-
tered (50 mg/kg, i.v.) if the animals showed a nociceptive response
to a pinching of the hind paw. The in vivo extracellular electro-
physiological recording of dorsal raphe nucleus neurons was
performed using micropipettes prepared as previously described
(Aghajanian and Haigler, 1974). A small hole was drilled on the
midline suture of the skull, 0.5–1.0 mm anterior to lambda. Slow
stereotaxic descents were made (5.5–6.5 mm ventral to the skull
surface), and a spontaneously active neuron was considered to be
serotonergic if it met the following criteria: a slow, regular ﬁring
rate (0.5–2.5 Hz) and a positive action potential of 0.8–1.2 ms in
duration. Animals were treated subcutaneously (1 ml/kg, s.c.) with
0.9% w/v of saline (vehicle), vilazodone (0.63 or 2.1 mmol/kg),
paroxetine (13 mmol/kg), or ﬂuoxetine (29 mmol/kg), administered
once (acute group) or once daily for 3 days (subchronic group).
Electrophysiological assessments were made at 4 h and 24 h after
a single dose (acute group) or 4 h and 24 h after 3 days of dosing
(subchronic group). In these experiments, a single spontaneously
active 5-HT neuron in the DRN was isolated from each animal and a
stable baseline was recorded for at least 3 min prior to administering
8-OH-DPAT. Subsequently, 8-OH-DPAT (1 dose per min) was given
via the tail vein (doses of 3.8, 7.6, 14.2, 28.4, 56.8 or 113.6 nmol/kg
dissolved in 0.9% saline with each injection being 0.05 ml) until the
ﬁring of the neuron was completely suppressed. Only one neuron
was recorded from each animal. The mean dose of 8-OH-DPAT
required to produce a 50% reduction in the ﬁring rate of dorsal
raphe 5-HT neurons (50% inhibitory dose [ID50]) in the different drug
groups was determined by using the curve ﬁtting program of Prism
Graph Pad 3.1 (GraphPad Software, Inc, La Jolla, CA). A decrease in 5-
HT1A autoreceptor sensitivity was measured as a signiﬁcant increase
in the ID50 of 8-OH-DPAT in drug-treated (compared with vehicle-
treated) animals. At the completion of an experiment, the anatomic
location of the 5-HT neurons isolated was determined by passing
a –20 mA current through the recording electrode for 10 min, which
resulted in the deposition of a discrete spot of fast green. Animals
were then overdosed with chloral hydrate and perfused transcar-
dially with a 10% formalin solution (pH 7.0, phosphate-buffered
saline). The brains were removed and serial coronal sections were cut
at 50 mm intervals, stained with cresyl violet, and counterstained
with neutral red. Sections were scanned for a dye spot using a light
microscope.
2.4. Neurochemical ex vivo determination of 5-HT reuptake
inhibition
PCA (5 mg/kg, i.p.) was dissolved in saline and injected in
a volume of 5 ml/kg body mass 3 h before euthanasia by decapita-
tion. Vilazodone was dissolved in 100% dimethylsulfoxide and
diluted with 1,2-propanediol to give a 1:1 (v/v) dilution, and the
SSRIs were dissolved in pure 1,2-propanediol. The experimental
drugs were administered (2 ml/kg, s.c) 3.5, 5, 8, or 18 h before
decapitation. The dosing regimens used (mmol/kg) were: vilazo-
done: 0.21, 0.63, 2.1, 6.3, 21, 63, and 210; ﬂuoxetine: 0.87, 2.9, 8.7,
Fig. 1. Electrophysiological effects of vilazodone (0.63; 2.1 mmol/kg), paroxetine
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0.29, 0.88, 2.9, 8.8, 29, 88, and 290; and paroxetine: 0.080, 0.27, 0.80,
2.7, 8.0, 27, and 80. Four doses of each drug were tested at each of
the 4 time points. Thus, in the interaction experiments, rats were
pre-treated 3.5–18 h with vilazodone or the reference SSRIs and co-
treated with PCA 3 h before euthanasia. Vehicle controls received
vehicle and saline at the appropriate times, and the PCA controls
were pre-treated with the drug solvent and received PCA 3 h before
decapitation. In separate experiments, it was conﬁrmed that the
experimental drugs alone did not signiﬁcantly alter hypothalamic
5-HT levels (results not shown). A typical experiment comprised 25
rats, i.e., 3 vehicle controls (basal hypothalamic 5-HT levels, mean:
900–1000 ng/g hypothalamus fresh mass), 6 PCA-alone controls
(depleted stores, mean: 400–500 ng/g) and 4 rats per each of the 4
co-treatment groups (mean: depending on uptake inhibition in the
range of 400–1000 ng/g). Treatments, euthanasia, tissue dissection
and workup were carried out according to a minute-by-minute
time scheme. The interaction study with R-()-fenﬂuramine as the
releasing agent was carried out in the same way as the PCA study.
Vilazodone was administered s.c. into the neck 5.5 h before and R-
()-fenﬂuramine, 10 mg/kg s.c. into the ﬂank, 5 h before decapita-
tion. Hypothalamus, frontal cortex and striatum from each rat were
analyzed in this study.
Brain areas were dissected as described by Glowinski and Iversen
(Glowinski and Iversen, 1966). Tissue samples were dissected out on
ice and immediately processed for high-performance liquid chro-
matography (HPLC) analysis. 5-HT concentration was determined by
an automated reverse-phase/ion pair, direct-injection HPLC method
(Seyfried et al., 1986) within a 25 min run and electrochemical
detection. N-Methyldopamine or N-ω-methylserotonin were used as
internal standards, and the recovery rates were 495%.
Antagonism of PCA-induced 5-HT depletion was calculated
in the following way: (Xdrug+PCAXPCA)100/(XcontrolsXPCA), X
being the means of each drug group. ID50 values and conﬁdence
intervals were calculated by using a nonlinear ﬁt to the Hill
equation (Mathematica 8, Wolfram Research Inc., Champaign, IL).(13 mmol/kg), ﬂuoxetine (29 mmol/kg), or vehicle on the inhibition of ﬁring (ID50) by
intravenous 8-OH-DPAT at 4 h and 24 h after (A) acute or (B) subchronic administra-
tion. The ﬁring rate of a single, spontaneously active dorsal neuron was measured in
each animal. The values are the means7S.E.M. of 10 rats. *Po0.01 versus vehicle.2.5. Statistical analysis
For the electrophysiological experiments, data were analyzed
by using a one-way analysis of variance (ANOVA), and post hoc
tests were conducted by using the Student–Newman–Keuls test.
For the neurochemical experiments, ANOVA was performed fol-
lowed by Dunnett's test for comparison of individual dose groups
to the appropriate controls.3. Results
3.1. 8-OH-DPAT-induced inhibition of dorsal raphe nucleus
5-HT neuron activity
Statistical analyses indicated that there was a signiﬁcant effect
of drug administration on the response of serotonergic dorsal
raphe neurons to i.v. 8-OH-DPAT 4 h after administration
(F4,45¼17.44, Po0.0001, one-way ANOVA). Subsequent post hoc
tests revealed that 0.63 or 2.1 μmol/kg s.c. of vilazodone signiﬁ-
cantly increased the ID50 value of i.v. 8-OH-DPAT (2–3-fold)
compared with animals treated with vehicle (Student–Newman–
Keuls values of 17.4 and 48.7). In contrast, neither ﬂuoxetine
(29 μmol/kg) nor paroxetine (13 μmol/kg) signiﬁcantly altered
the ID50 value of i.v. 8-OH-DPAT for serotonergic neurons in the
DRN compared with vehicle-treated animals. Fig. 1A summarizes
the effects of the acute administration of vehicle, ﬂuoxetine,
paroxetine, and vilazodone on the (ID50) values of i.v. 8-OH-DPAT.There was also a signiﬁcant effect of treatment on the ID50 value
of i.v. 8-OH-DPAT for serotonergic neurons in the DRN 4 h after
subchronic administration (one s.c. injection per day for 3 days;
F4,45¼35.8, Po0.0001, one-way ANOVA) (Fig. 1B). Statistical analyses
indicated that both 0.63 and 2.1 μmol/kg of vilazodone (Student–
Newman–Keuls values of 45.4 and 87.3, respectively), but not
paroxetine or ﬂuoxetine, produced a signiﬁcant 3–4-fold shift in
the ID50 value of 8-OH-DPAT, compared with vehicle-treated animals.
In contrast, 24 h following acute drug administration, none of the
compounds produced a signiﬁcant change in the ID50 of 8-OH-DPAT
(F4,45¼0.67, P¼0.617) (Fig. 1A). However, there was an effect of
treatment on the ID50 values of 8-OH-DPAT 24 h after subchronic
administration (F4,45¼7.62, Po0.001, one-way ANOVA). The sub-
chronic administration of 0.63 or 2.1 μmol/kg of vilazodone produced
a signiﬁcant increase in the ID50 of 8-OH-DPAT 24 h after the
last injection (Student–Newman–Keuls values of 10.4 and 19.5).
In contrast, the subchronic administration of paroxetine or ﬂuoxetine
(Fig. 1B) did not signiﬁcantly alter the ID50 value of 8-OH-DPAT. Thus,
vilazodone produced a long-lasting effect on 8-OH-DPAT-induced
inhibition of neuronal DRN activity in anesthetized rats.
3.2. PCA and R-()-fenﬂuramine-induced 5-HT depletion
in rat brain
Vilazodone dose-dependently inhibited PCA-induced 5-HT
depletion in rat hypothalamus with an ID50 of 1.49 mmol/kg when
Table 1
Duration of action of vilazodone and various SSRIs to prevent PCA-induced rat hypothalamic 5-HT depletion.
Drug ID50 (mmol/kg s.c.) (95% conﬁdence intervals)
3.5 h 5 h 8 h 18 h post-application
Vilazodone 1.49 (1.30–1.65) 0.46 (0.25–0.73) 1.17 (1.09–1.28) 169 (100–1)
Fluoxetine 6.88 (5.93–7.69) 4.80 (3.85–5.70) 7.63 (7.61–7.66) 22.7 (8.96–28.9)
Sertraline 1.81 (0.99–2.71) 1.37 (0.76–2.42) 2.42 (1.66–3.33) 9.51 (3.97–25.3)
Citalopram 1.90 (0.86–3.36) 2.64 (1.46–5.11) 7.97 (2.79–22.3) 57.7 (47.9–71.3)
Paroxetine 0.45 (0.37–0.53) 0.27 (0.21–0.32) 0.69 (0.45–1.17) 37.9 (13.6–72.3)
The values in the table represent the ID50 values (50% prevention of 5-HT depletion) and 95% conﬁdence intervals (in parentheses) in mmol/kg s.c. Four doses of each drug
were tested at each of the 4 time points. Doses were chosen to obtain dose response curves ranging from very low to at least 100% prevention of 5-HT depletion except for
vilazodone, which only produced a 55% prevention at the highest dose of 210 mmol/kg 18 h post-application. Four rats were used for each drug plus PCA dose group, 6 rats for
the PCA alone and 3 rats for the vehicle control group.
Fig. 2. Antagonism by vilazodone of R-(–)-fenﬂuramine-induced rat hypothalamic
5-HT depletion. Vilazodone (A) 0.021–0.63 mmol/kg s.c., and (B) 0.21–6.3 mmol/kg s.
c., was administered into the neck 5.5 h before euthanasia. R-()-fenﬂuramine
administration (10 mg/kg s.c. into the ﬂank) was administered 5 h before eutha-
nasia. Number of rats were: 3 (controls), 6 (R-()-fenﬂuramine) and 4 (vilazodone
plus R-()-fenﬂuramine). **Po0.01 versus controls. +Po0.05; ++Po0.01 versus
R-(–)-fenﬂuramine alone group (t-Dunnett).
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of this effect is shown in Table 1. Although vilazodone produced
signiﬁcant inhibition of PCA-induced 5-HT depletion 3.5 h, 5 h,and 8 h after administration, its potency was more than 100-fold
lower when evaluated 18 h after administration (ID50¼169 mmol/kg).
The duration of action of citalopram and paroxetine were similar
to that of vilazodone, whereas ﬂuoxetine and sertraline had
longer-acting effects, with relatively low ID50 values at 18 h post-
administration.
In agreement with the PCA results, R-()-fenﬂuramine-
induced hypothalamic 5-HT depletion was inhibited with an ID50
of 0.18 mmol/kg s.c. (Fig. 2A); the ID100 was 0.63 mmol/kg s.c.
Increasing this dose 10-fold did not change the results (Fig. 2B).
Similar values were obtained for frontal cortex and striatum (0.23
and 0.19 mmol/kg s.c., respectively; results not shown). In a
separate study (in the absence of fenﬂuramine), subchronic
administration of supramaximal doses of vilazodone alone (up to
21 mmol/kg, s.c., daily for 3 days) did not deplete tissue 5-HT in the
rat striatum and frontal cortex 3 h or 24 h after the last application
(results not shown).4. Discussion
The present electrophysiological results show, for the ﬁrst time,
direct in vivo interactions of vilazodone with the 5-HT1A receptors
on DRN neurons, and support conclusions of earlier in vivo studies,
using indirect behavioral and neurochemical models (Bartoszyk
et al., 1996, 1997) and microdialysis studies (Hughes et al., 2005;
Page et al., 2002; Roberts et al., 2005). Importantly, the results
indicate that the reduction of sensitivity of 5-HT1A autoreceptors
on rat dorsal raphe neurons in the current study is unrelated to the
inhibition of 5-HT uptake, since the conventional uptake inhibitors
ﬂuoxetine and paroxetine did not signiﬁcantly alter the ID50
for 8-OH-DPAT, a ﬁnding consistent with that of Czachura and
Rasmussen (2000).
It can be estimated that the electrophysiological model
used here is quite sensitive, approximately in the same range as
microdialysis studies, where threshold doses of vilazodone for
increasing rat hippocampal 5-HT output were also 0.63 μmol/kg
(Page et al., 2002). In the same dose range, vilazodone markedly
inhibited 5-HT uptake in vivo, as reﬂected in the PCA model
(Table 1). Also, in vitro, both the afﬁnity for the 5-HT1A receptor
and the inhibition of 5-HT uptake using native rat brain mem-
branes, are in the same range with IC50 values of 0.5 and 0.2 nM,
respectively (Bartoszyk et al., 1996).
Similar to other in vivo studies, the partial agonist vilazodone
reduces the sensitivity of the 5-HT1A receptors in the in vivo
electrophysiological model and thus is distinct from the 5-HT1A
agonist 8-OH-DPAT. Thus, it has been shown that vilazodone does
not induce the so-called 5-HT syndrome in rats, but instead
antagonizes the actions of 8-OH-DPAT in this model (Page et al.,
2002). In contrast, in various in vitro models, vilazodone exhibits
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(Dawson and Watson, 2009; Hughes et al., 2005; Page et al., 2002).
Depending on the in vitro assay system utilized, the intrinsic
activity of vilazodone ranged from 0.61 to 100 and pEC50 values
from 8.1 to 9.0 (for review, see Dawson and Watson (2009)). Based
on the in vitro data, one would expect to also have observed
5-HT1A agonistic activity in vivo. Therefore, it has been speculated
that metabolites of vilazodone might explain the in vitro/in vivo
discrepancies. However, in pharmacokinetic studies using [14C]-
labeled vilazodone, more than 90% of the radioactivity in rat brain
consisted of unchanged vilazodone (Forest Laboratories, data
on ﬁle). Furthermore, one of the primary active metabolites,
6-hydroxy-vilazodone (Hewitt et al., 2001), is 410 times less
potent than vilazodone in inhibiting 5-HT uptake (IC50¼9 nM) and
at 5-HT1A receptors (IC50¼8.4 nM) (H. Boettcher, personal com-
munication). Therefore, it is unlikely that active metabolites of
vilazodone play a role in its in vivo CNS effects.
A more likely explanation for the different activities seen
in vitro versus in vivo is due to possible differences in receptor
reserves found in vitro in membrane preparations relative to
in vivo environments, i.e., the percentage of the receptor popula-
tion necessary to elicit a full agonist response. It is conceivable that
vilazodone, being a 5-HT1A receptor partial agonist, has a markedly
lower receptor reserve in vivo than 8-OH-DPAT, but due to its
higher afﬁnity, displaces full agonists from binding sites and
decreases the receptor occupancy of 8-OH-DPAT. Receptor reserve
has been shown to be variable in different recombinant and
various native tissue in vitro systems, which adds a complication
to interpreting these data (Dawson and Watson, 2009). Appar-
ently, in vitro agonist binding assays measuring the effect on
[35S]-GTP-γ-S binding might have limited predictive value for
in vivo experiments.
Measurement of 5-HT1A agonist activity of vilazodone in vivo
can be challenging due to its potent inhibition of serotonin
reuptake, which may potentially confound any direct assay of 5-
HT1A agonist activity. Currently, it is not possible to estimate the
in vivo intrinsic activity of vilazodone at the 5-HT1A receptor as
receptor inactivation studies similar to other 5-HT1A partial
agonists (Cox et al., 1993; Meller and Bohmaker, 1994; Meller
et al., 1990) are lacking.
It has been suggested that rapid desensitization of 5-HT1A
autoreceptors may explain vilazodone's in vivo proﬁle, notably the
earlier microdialysis ﬁndings that suggested vilazodone increased
serotonergic output in the prefrontal cortex of rats. (Dawson and
Watson, 2009; Hughes et al., 2005; Page et al., 2002). Indeed, the
desensitization of these autoreceptors is believed to be a critical
rate-limiting step in the process of augmenting 5-HT neurotransmis-
sion by antidepressant drugs (Blier and Ward, 2003). The results
presented herein do not exclude this interpretation: following a 24 h
washout period, there was still a 1.7-fold and a 2-fold increase in the
ID50 values of 8-OH-DPAT when vilazodone was given subchroni-
cally at doses of 0.63 and 2.1 mmol/kg s.c. per day, respectively,
whereas paroxetine and ﬂuoxetine were inactive. This lack of
desensitizing activity of paroxetine and ﬂuoxetine is also unrelated
to their duration of action as the ratio of the ID50 values at 18 h and
3.5 h is 3.3 for ﬂuoxetine and 84 for paroxetine (Table 1), reﬂecting
ﬂuoxetine's long duration of action as compared with that of
paroxetine and vilazodone (ratio 114). In order to obtain desensitiz-
ing effects comparable to vilazodone, ﬂuoxetine has to be given for
much longer periods. Indeed, chronic treatment with 29 mmol/kg s.c.
per day for 21 days results in a 3-fold increase in the ID50 of 8-OH-
DPAT whereas vilazodone, 21 or 63 mmol/kg s.c., also given for 21
days, produces an 8–10-fold increase, which is apparently the
maximal effect of vilazodone in this model (Ashby, unpublished
results). Similarly, Hughes et al. (2007) in microdialysis studies
found that chronic paroxetine (26 mmol/kg p.o., daily for 21 days)was required for a modest 1.5-fold increase in cortical 5-HT. The
results in the PCA model, where vilazodone was inactive 18 h post-
administration (Table 1), underlines the view that rapid 5-HT1A
autoreceptor desensitization may be responsible for the sustained
effects of vilazodone in the electrophysiological model.
Since the plasma half-life of vilazodone in rats is relatively
short and was estimated in rat pharmacokinetic studies following
a single injection (1 mg/kg i.v.) to be 1.4 h (Forest Laboratories,
data on ﬁle), one can speculate that virtually no vilazodone should
be present at 24 h post-administration. However, pharmacokinetic
studies using s.c. administration are not available and rats were
treated for three days u.i.d. in the electrophysiological studies,
so we cannot exclude that some accumulation of vilazodone might
have occurred.
It is difﬁcult to determine if desensitization also plays a role in
the experiments with the 4 h washout period. Notwithstanding
the above caveats, if one considers the results of the in vitro
agonist assays, vilazodone's agonist potency is at least one order of
magnitude greater than that of 5-HT or 8-OH-DPAT (Dawson and
Watson, 2009; Hughes et al., 2005), which would support the
desensitization hypothesis. Additionally, the afﬁnity of vilazodone
for the 5-HT1A receptor is at least one order of magnitude higher
than 5-HT and 8-OH-DPAT, both of which compete for the 5-HT1A
binding site, lending further support for desensitization. Intrigu-
ingly, the onset of the purported vilazodone-induced desensitiza-
tion must be very fast, since 40 min after an acute injection of
6.3 mmol/kg i.p. vilazodone, a maximally 7-fold increase in 5-HT
levels occurs in frontal cortex dialysates (van Amsterdam, personal
communication), which is in agreement with ﬁndings of Page et al.
(2002). Alternatively, rapid desensitization could occur via recep-
tor internalization (Riad et al., 2001) or by attenuation of receptor
coupling to the G protein, although these assumptions are less
parsimonious.
To exclude false positive results, especially in the previous
microdialysis studies, it is imperative to rule out the possibility
that vilazodone administration results in 5-HT release. This is
unlikely as the subchronic treatment with supramaximal doses
(up to 21 mmol/kg s.c. daily for 3 days) did not deplete tissue 5-HT
levels in either the cortex or striatum (brain areas often chosen for
5-HT microdialysis studies) 3 h and 24 h after the last administra-
tion (results not shown). Furthermore, vilazodone completely
antagonized the 5-HT depleting actions of the prototypical 5-HT
releaser R-()-fenﬂuramine in rat hypothalamus (Fig. 2A), even at
doses 10-fold higher than the ID100 in this model (Fig. 2B).
Currently, no clinical studies have been conducted to speciﬁ-
cally determine if vilazodone produces an early onset of antide-
pressant action in patients with major depressive disorders.
In both Phase III clinical trials the antidepressant efﬁcacy primary
endpoint was statistically signiﬁcant in favor of vilazodone com-
pared with placebo (Khan et al., 2011; Rickels et al., 2009). The
difference versus placebo was statistically signiﬁcant at Week 1
(the earliest time point measured) in one trial, but not the other.
Therefore, the hypothesis that vilazodone produces a rapid onset
of antidepressant action in patients remains to be tested.5. Conclusion
In summary, the present electrophysiological experiments
indicate that vilazodone reduces the sensitivity of 5-HT1A auto-
receptors in the DRN more rapidly than the two SSRIs ﬂuoxetine
and paroxetine. This effect could occur by either direct interaction
with, or rapid desensitization of these receptors, and cannot
be ascribed to vilazodone's 5-HT reuptake-inhibiting properties.
Further clinical studies would be needed to determine whether
C.R. Ashby Jr. et al. / European Journal of Pharmacology 714 (2013) 359–365364vilazodone produces an early onset of efﬁcacy in patients with
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